A recent phase III, randomized, controlled clinical trial of 458 patients found that topical 0
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have only approved topical minoxidil (MNX) and oral finasteride (FNS)
In the pivotal phase 3 clinical trials, finasteride arrested AGA in ≥90% of men and promoted regrowth in 48% at 12 months and 66% at 48 months
Finasteride Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomised, controlled clinical trial Journal of the
placebo group, with no
Clinical settings use systemic finasteride, a 5-reductase inhibitor and 4-aza-3-oxosteroid molecule, to treat benign prostatic hyperplasia (BPH) and AGA
Keywords: Androgenetic alopecia, finasteride, pilous Go to: Introduction What
Common AGA treatments include finasteride (an oral 5-α-reductase type II inhibitor), minoxidil (a topical pyrimidine derivative), and hair
However, the best concentration of combination treatment requires further studies with sound methodological quality
The name of this product is Breezula® and it is a novel androgen receptor inhibitor
Methods: Randomized controlled trials of dutasteride and finasteride for treating AGA were searched using MEDLINE, EMBASE, and the Cochrane
, Studies show that topical finasteride appears to have results equivalent to oral finasteride in AGA,[5,6] and has better tolerance
25% w/w Finasteride Recruiting Phase 3 Trials for Androgenetic Alopecia (AGA) Treatment
A phase-3, randomized control trial on 458 males was done to evaluate the efficacy and safety profile of 0
FNS inhibits 5-reductase type 2 competitively to stop testosterone from being converted to dihydrotestosterone and significantly lower blood DHT levels
The phase IV clinical study analyzes what interactions people who take Omega-3 fatty acid and Finasteride have
Methods: Forty men aged 18-60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/minoxidil or minoxidil solution twice daily
Indications Status Purpose Phase; DBCOND0064452 (Androgenetic Alopecia (AGA)) Drugs; NCT01391156: Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss: Finasteride (DB01216 The 1-mg dose was thus chosen as optimal for further study in subsequent Phase III studies in men with AGA
Hair count and width increased dose dependently with dutasteride
4
5 mg/day generated a superior hair count to finasteride 5 mg at 12 and 24 weeks (Olsen et al
Change from baseline in target area hair count (TAHC) at week 24 (primary efficacy endpoint) was significantly greater with topical finasteride than placebo (adjusted mean change 20
Citation 6, Citation 7 Observing related literature on the effectiveness of finasteride in AGA, there was no increase in the incidence of adverse reactions related to sexual functions during the course of long-term finasteride treatment
3 Plastic Surgery Department, Southwest Hospital, Army Military Medical University, 30 Gaotanyan Street, Shapingba District, In patients with AGA, the combination treatment of finasteride and topical minoxidil has better therapeutic efficacy than and similar safety as monotherapy